Bli medlem
Bli medlem

Du är här

2016-05-10

AroCell: Interim report, 1 January - 31 March 2016

· Net sales were TSEK 0 (0)
· Loss after financial items was TSEK -2,842 (-2,402)
· Earnings per share where SEK -0.10 (-0.10)
· Cash flow from operating activities was TSEK -1,272 (-3,255)
· Scale-up of production processes for TK 210 ELISA proceeds
according to plan

· The Ethical review board for Stockholm South General Hospital
(Södersjukhuset) approved the start of a clinical study regarding
follow-up of prostate cancer patients with TK 210 ELISA

· The Ethical committee for the University Hospital of Helsinki
approved the start of a clinical study regarding follow-up of sarcoma
patients with TK 210 ELISA

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized
modern blood tests to support the prognosis and follow-up of cancer
patients. AroCell's new technology is based on patented methods to
measure TK1 protein levels, which provide valuable information
concerning the speed of cell turnover. A tumor has high cell turnover
(speed of cell division and cell death) and as a result TK1 can be
detected in the blood with a simple laboratory test, called TK 210
ELISA. The test provides valuable clinical information for prognosis
and optimization of treatment strategy. The test may also be used for
monitoring disease relapse. AroCell (AROC) is listed on the
AktieTorget marketplace in Sweden and has about 2,800 shareholders.
For more information, please see
(http://www.arocell.com/)www.arocell.com.

Significant events during the reporting period

· The Ethical review board for Stockholm South General Hospital
(Södersjukhuset) approved the start of a clinical study. In this
study, patients with prostate cancer will be evaluated from diagnosis
through treatment and follow-up with the TK 210 ELISA. The study is
estimated to take two years.

· The Ethical committee of the University Hospital of Helsinki
approved the start of a clinical study regarding sarcoma cancer
patients. The patients will be evaluated with the TK 210 ELISA and
the study is estimated to take two years.

Significant events after the reporting period

· One of the first clinical studies using the TK 210 ELISA was
published in the scientific journal Tumor Biology. The study
established that the TK 210 ELISA test show higher clinical
sensitivity for patients with early stage breast cancer compared with
the currently most used biomarker CA15-3.

· The European Patent Office approved the AroCell AB patent
regarding an invention relating to methods to produce antibodies for
exposed thymidine kinase 1 (TK1) derived peptides, ligands and
methods employing these.

· Martin Shaw joins and reinforces the management team at AroCell as
Business Development Manager. Martin has over 40 years of experience
in the development and introduction of novel biomarker assays to the
pharmaceutical, biotechnology and laboratory medicine industries.

Comments from Jan Stålemark, CEO of AroCell

We continue to follow the clinical development plan for our TK 210
ELSIA test in order to quickly attain market acceptance. It is
important that we can provide clinicians with guidelines regarding
how our test can be used in various clinical applications. This means
that we must obtain data through our clinical studies in order to
provide clinicians with the means to interpret results of the TK 210
ELISA test in the prognosis, treatment and follow-up of cancer
patients.

The recently published clinical study in Tumor Biology on TK 210 ELISA
with breast cancer patients is an example of what can be generated in
the clinical development plan. We can now use these results to define
an application for our product. The study also provides us with the
opportunity of utilizing the results in AroCell's marketing
materials.

Participation in scientific congresses throughout the coming years
will give us opportunities to meet potential customers and
distributors. We have chosen to focus on meetings with a research
profile, in the forefront of cancer research. We will soon
participate in is the Biomarkers & Diagnostics World Congress in
Philadelphia USA, May 16-19. We have new marketing material and will
have a strategically well located exhibition stand, together with a
sponsored presentation of AroCell technology in the official congress
program. We have planned several similar congress activities and we
hope to gain many new valuable contacts.

Martin Shaw has joined and reinforces the management team at AroCell
as Business Development Manager. Martin has over 40 years of
experience within development and introduction of novel biomarker
assays to the pharmaceutical, biotechnology and laboratory medicine
industries.

The European Patent Office has granted our patent in connection with
exposed proliferation related peptides. This patent provides us with
additional protection for our unique TK 210 ELISA test.

Jan Stålemark
CEO

Essential risks

Financial risks
AroCell's business activities are based on external financing. To
date, the company has been successful in obtaining financing, but
there are no guarantees of this happening in the future in a way that
is advantageous to the company's shareholders. A sufficiently serious
failure in future financing may affect the company's development and
market value.

Development and production risks

Development and transfer to production are always associated with
risks. A product manufactured at production scale does not always
display exactly the same characteristics as one manufactured at
research scale. Developing future products may also prove to be more
complicated and take longer than expected.

Commercialization risks

There is always a risk that the products AroCell has developed will
not achieve the expected positive reception on the market and that
the product will need longer to gain acceptance. Particularly in the
early stages, the quantity of products sold may then be lower and the
time it takes to establish the product on the market may be longer
than the company allowed for in its sales estimates.

In addition, there are risks associated with patent security and how
the market assesses studies, approvals and certifications. Taking
risk factors into consideration in decision processes and when
designing routines and drawing up documentation means that the risks
are assessed and their effects can be minimised and, to some extent,
avoided.

Accounting principles

The interim report has been prepared in accordance with
"Årsredovisningslagen och Bokföringsnämndens allmänna råd, BFNAR
2012:1 Årsredovisning och koncernredovisning (K3)" and with the same
accounting principles as in the company's annual report 2015.

The share

AroCell AB (publ) was listed on the AktieTorget marketplace on 25 May
2011. At 31 March 2016, there were 28,674,506 shares (quota value SEK
0.10)

Contact information

Jan Stålemark, CEO

info@arocell.com

+46 (0)706-92 62 06

www.arocell.com

AroCell AB (publ)

Virdings Allé 32B

SE-754 50 UPPSALA

SWEDEN

Financial calendar

2016-05-18 Annual general meeting 2016

2016-08-25 Interim report no. 2 2016

2016-11-17 Interim report no. 3 2016

2017-02-16 Year-End report 2016

The interim report has not been reviewed by the company's auditor.

Submission of interim report

Uppsala, 10 March 2016

The Board of Directors

-----------------------------------------------------------
http://news.cision.com/arocell/r/interim-report--1-january---31-march-20...
http://mb.cision.com/Main/1010/2006394/513909.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.